Tripep AB (publ.)—Interim Report—January - March 2006

• The company had no net sales in the period. • Research and development costs for the first quarter 2006 were SEK 3.3 million (2.1 m). • The results of the double-blind trial on alphaHGA indicated no significant reduction of patient HIV levels in serum, which consequently led to a complete write-down of all capitalised expenditure on the alphaHGA project, which affects the results negatively by SEK 35.0 m. • The loss after tax for the first quarter 2006 was SEK -42.4 million (-5.2 m). • Earnings per share for the first quarter 2006 were SEK -1.99 (-0.32). • Pursuant to EGM authorisation, Tripep's board consummated the new issue of 2 million shares. This issue was targeted at a limited group of investors, raising the company approximately SEK 24 m after issue costs. • TO 1 series F warrants matured on 31 January 2006, and at that time, had raised the company approximately SEK 10 m. • A quarter of breakthroughs for ChronVac-C® o Collaboration agreement with InovioTM on joint clinical development signed in January 2006; o In February 2006, Tripep was enabled to enter toxicological studies of ChronVac-C® in collaboration with Visionar AB; o Tripep secured its most important patent so far on ChronVac-C® in March 2006. For more information, please contact Jan Nilsson, Chief Executive Officer Tel: +46 (0)8 449 84 82, mobile: +46 (0)70 466 31 63 e-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research Tel: +46 (0)8 5858 1313, mobile: +46 (0)70 928 05 28 e-mail: anders.vahlne@ki.se